This company listing is no longer active
DBV Technologies Past Earnings Performance
Past criteria checks 0/6
Key information
10.8%
Earnings growth rate
28.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -10.6% |
Return on equity | -94.4% |
Net Margin | -929.9% |
Next Earnings Update | 03 Nov 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How DBV Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 8 | -77 | 29 | 59 |
31 Mar 22 | 5 | -85 | 32 | 60 |
31 Dec 21 | 6 | -98 | 35 | 70 |
30 Sep 21 | 2 | -124 | 43 | 81 |
30 Jun 21 | 4 | -131 | 42 | 91 |
31 Mar 21 | 9 | -148 | 37 | 96 |
31 Dec 20 | 11 | -160 | 45 | 102 |
30 Sep 20 | 17 | -161 | 54 | 100 |
30 Jun 20 | 16 | -171 | 63 | 102 |
31 Mar 20 | 16 | -169 | 74 | 110 |
31 Dec 19 | 15 | -172 | 75 | 111 |
30 Sep 19 | 12 | -176 | 77 | 112 |
30 Jun 19 | 13 | -198 | 90 | 122 |
31 Mar 19 | 13 | -191 | 87 | 119 |
31 Dec 18 | 13 | -190 | 87 | 120 |
30 Sep 18 | 11 | -178 | 77 | 117 |
30 Jun 18 | 11 | -172 | 68 | 117 |
31 Mar 18 | 11 | -182 | 69 | 126 |
31 Dec 17 | 12 | -177 | 64 | 124 |
30 Sep 17 | 11 | -169 | 63 | 119 |
30 Jun 17 | 11 | -157 | 61 | 109 |
31 Mar 17 | 9 | -135 | 54 | 91 |
31 Dec 16 | 8 | -121 | 51 | 81 |
30 Sep 16 | 8 | -109 | 47 | 72 |
30 Jun 16 | 8 | -88 | 39 | 59 |
31 Mar 16 | 8 | -72 | 31 | 50 |
31 Dec 15 | 7 | -49 | 20 | 36 |
30 Sep 15 | 6 | -40 | 16 | 31 |
Quality Earnings: DBVT.F is currently unprofitable.
Growing Profit Margin: DBVT.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DBVT.F is unprofitable, but has reduced losses over the past 5 years at a rate of 10.8% per year.
Accelerating Growth: Unable to compare DBVT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBVT.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (95.6%).
Return on Equity
High ROE: DBVT.F has a negative Return on Equity (-94.38%), as it is currently unprofitable.